Editorial: Biomarkers are here to stay for clinical research and standard care

Journal of Thoracic Oncology

Volumn 5, Issue 8, 2010, Pages 1113-1115

  Bunn, Paul A ^a   Hirsch, Fred R ^a   Doebele, Robert C ^a   Camidge, D Ross ^a   Varella Garcia, Marileila ^a   Franklin, Wilbur ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; N [4 (3 CHLORO 4 FLUOROANILINO) 7 (TETRAHYDRO 3 FURYLOXY) 6 QUINAZOLINYL] 4 DIMETHYLAMINO 2 BUTENAMIDE; PHARMACOLOGICAL BIOMARKER; PLASMA PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; BIOLOGICAL MARKER;

CANCER CHEMOTHERAPY; CLINICAL RESEARCH; CLINICAL TRIAL; DISEASE SEVERITY; DRUG APPROVAL; DRUG SCREENING; EDITORIAL; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; INDUCED MUTATION; LUNG NON SMALL CELL CANCER; NEEDLE BIOPSY; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT SELECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEOMICS; QUALITY OF LIFE; TUMOR BIOPSY; TUMOR GENE; TUMOR REGRESSION; HEALTH CARE DELIVERY; MEDICAL RESEARCH; METHODOLOGY; NOTE; STANDARD;

BIOLOGICAL MARKERS; BIOMEDICAL RESEARCH; DELIVERY OF HEALTH CARE; HUMANS;

EID: 77955109217     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181e7616e     Document Type: Editorial

References (21)

1. Subramanian J, Madadi AR, Dandona M, et al. Review of ongoing clinical trials in non small cell lung cancer (NSCLC). A status report for 2009 from the ClinicalTrials.gov website. J Thorac Oncol 2010;5:1116-1119.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:1-7.
3. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-2150.
4. Curran WJ Jr, Schiller JH, Wolkin AC, et al. Addressing the current challenges of non-small-cell lung cancer clinical trial accrual. Clin Lung Cancer 2008;9:222-226.
5. Lynch TJ, Nell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non- small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
6. Paez G, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304: 1497-1500.
7. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
8. Kobayashi K, Inoue A, Macmondo M, et al. First line gefitinib versus fist line chemotherapy by carboplatin plus paclitaxel in non-small cell lung cancer patients with EGFR mutations. A phase III study (002) by North East Japan Gefitinib Study Group. J Clin Oncol 2009;27:411S.
9. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJT0G3405): an open label, randomized phase 3 trial. Lancet Oncol 2010;11:121-128.
10. Lee JS, Park J, Kim SW, et al. A randomized phase III study of gefitinib (IRESSA®) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. J Thorac Oncol 2009;4:S283.
11. Hirsch FR, Dziadziuszko R, Varella-Garcia M, et al. Randomized phase II study of erlotinib (E) or intercalated E with carboplatin/paclitaxel in chemonaive advanced NSCLC. Correlation of biomarker status and clinical benefit. J Clin Oncol 2009;27:413S.
12. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448:561-566.
13. Camidge DR, Christensen J, Bang YJ, et al. Addressing right drug-right target-right patient in phase I studies to accelerate bench to clinical benefit time: ALK gene rearrangements and the development of PF- 02341066 in NSCLC. 2010;5:S233.
14. Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR. 21. J Clin Oncol 2008;26: 4268-4275.
15. Cappuzzo F, Coudert B, Wierzbicki R, et al. Efficacy and safety of erlotinib as first-line maintenance in NSCLC following non-progression with chemotherapy: results from the phase III SATURN study. J Thorac Oncol (meeting abstracts) 2009;4:S289.
16. Taguchi F, Solomon B, Gregori V, et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst 2007;99:838-846.
17. Carbone DP, Seymour L, Ding K, et al. Serum proteomic prediction of outcomes in advanced NSCLC patients treated with erlotinib/ placebo in the NCIC clinical trials group BR. 21 trial. J Thorac Oncol 2010;5:S80.
18. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-967.
19. Yang C, Hirsh V, Cadranel J, et al. Phase IIb/III double-blind randomized trial of BIBW2992, an irreversible dual inhibitor of EGFR and HER2 plus best supportive care (BSC) versus placebo plus erlotinib or gefitinib (LUX-lung1): a preliminary report. J Clin Oncol 2009;27:422s.
20. Kim ES, Herbst RS, Lee JJ, et al. The BATTLE trial (Biomarker- integrated approaches of targeted therapy for lung cancer elimination): personalizing therapy for lung cancer. AACR 101st Annual Meeting, April 17-21, 2010, Washington, DC.
21. Richardson F, Richardson K, Sennello G, et al. Biomarker analysis of tumor tissue from completely resected NSCLC patients enrolled in an adjuvant trial (RADIANT). J Thorac Oncol 2008;3:S269.